Acadia Pharmaceuticals | ACAD - Capital Ordinário





Capital Ordinário Alterar Data
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
ALKERMES USD 167.54M 1.08M 2026-06
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cara Therapeutics USD 9.38M 2.01K 2026-03
Corcept Therapeutics USD 107.33M 1.36M 2026-03
Cytokinetics USD 124.43M 2.17M 2026-03
Eisai JPY 282.46M 345K 2026-06
Eli Lilly USD 943.5M 3.33M 2026-03
Incyte USD 200.98M 1.03M 2026-06
J&J USD 2.41B 1.35M 2026-03
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.55M 50K 2026-06
Pfizer USD 5.7B 0 2026-06
Prothena USD 53.08M 756K 2026-03
PTC Therapeutics USD 82.88M 1.41M 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vanda Pharmaceuticals USD 58K 0 2024-12
Vertex Pharmaceuticals USD 253.3M 900K 2026-06